Section: Contact Information
First Name: Elizabeth (Lieke)
Last Name: Feijen
Institution: Emma Childrens hospital/ Academical Medical Center Amsterdam
Address 1: Meibergdreef 9
City: Amsterdam
State/Province/Region: International Location: Noord Holland
Country: NL
Zip/Postal Code: 1105 AZ
Phone Number: 0031205661417
Alternate Phone Number: 
Email Address: e.a.feijen@amc.uva.nl

Section: Project Requirements and Description

Group: Requirements to submit AOI
A comprehensive review of previously published data has been completed. : Yes
The specific aims are clear and focused. : Yes
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator. : Yes
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months. : Yes
Project Title: Anthracycline equivalent 2
Planned research population (eligibility criteria): Expanded CCSS cohort, plus external cohorts: St. Jude Lifetime Cohort (AOI discussed with Dr. Melissa Hudson) and DCOG LATER cohort
Proposed specific aims:
Determine if a more appropriate anthracycline cardiotoxicity equivalence formula can be derived based on the risk of clinical heart failure among childhood cancer survivors possibly for epirubicin, idarubicin and mitoxantrone in relation to doxorubicin. This project would extend our prior work examining daunorubicin and doxorubicin equivalence.
Will the project require non-CCSS funding to complete? : No
If yes, what would be the anticipated source(s) and timeline(s) for securing funding? :

Group: Does this project require contact of CCSS study subjects for:
Additional self-reported information: No
Biological samples: No
Medical record data: No
If yes to any of the above, please briefly describe. : 
**Group: What CCSS Working Group(s) would likely be involved? (Check all that apply)**

Second Malignancy: 
Chronic Disease: **Primary**
Psychology / Neuropsychology: 
Genetics: 
Cancer Control: 
Epidemiology / Biostatistics: **Secondary**

**Section: Outcomes or Correlative Factors**

Late mortality: **Secondary**
Second Malignancy: 

**Group: Health Behaviors**

Tobacco: 
Alcohol: 
Physical activity: 
Medical screening: 
Other: 
If other, please specify: 

**Group: Psychosocial**

Insurance: 
Marriage: 
Education: 
Employment: 
Other: 
If other, please specify: 

**Group: Medical Conditions**

Hearing/Vision/Speech: 
Hormonal systems: 
Heart and vascular: **Primary**
Respiratory: 
Digestive: 
Surgical procedures: 
Brain and nervous system: 
Other: 
If other, please specify: 

**Group: Medications**

Describe medications: 

**Group: Psychologic/Quality of Life**
BSI-18 : 
SF-36 : 
CCSS-NCQ : 
PTS : 
PTG : 
Other : 
If other, please specify:

**Group: Other**
Pregnancy and offspring:
Family history:
Chronic conditions (CTCAE v3):
Health status:

**Group: Demographic**
Age: Correlative Factors
Race: Correlative Factors
Sex:
Other:
If other, please specify:

**Group: Cancer treatment**
Chemotherapy: Correlative Factors
Radiation therapy: Correlative Factors
Surgery:

**Section: Anticipated Sources of Statistical Support**
CCSS Statistical Center:
Local institutional statistician: Yes
If local, please provide the name(s) and contact information of the statistician(s) to be involved:
Lieke Feijen with guidance of Leontien Kremer, Eric Chow and Wendy Leisenring
Will this project utilize CCSS biologic samples?: No
If yes, which of the following?:
If other, please explain:

**Section: Other General Comments**
Other General Comments: